Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells

Glioblastoma stem cells (GSCs), responsible for the dismal disease prognosis after conventional treatments, are driven by overactive signaling pathways, such as PI3K/ AKT/mTOR and RAS/RAF/MAPK. The objective of our study was to target in vitro-GSCs by combining metformin (Met) as a mTOR inhibitor, w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of B.U. ON. 2014-04, Vol.19 (2), p.502-511
Hauptverfasser: Aldea, Mihaela D, Petrushev, Bobe, Soritau, Olga, Tomuleasa, Ciprian I, Berindan-Neagoe, Ioana, Filip, Adriana G, Chereches, Gabriela, Cenariu, Mihai, Craciun, Lucian, Tatomir, Corina, Florian, Ioan-Stefan, Crivii, Carmen B, Kacso, Gabriel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 511
container_issue 2
container_start_page 502
container_title Journal of B.U. ON.
container_volume 19
creator Aldea, Mihaela D
Petrushev, Bobe
Soritau, Olga
Tomuleasa, Ciprian I
Berindan-Neagoe, Ioana
Filip, Adriana G
Chereches, Gabriela
Cenariu, Mihai
Craciun, Lucian
Tatomir, Corina
Florian, Ioan-Stefan
Crivii, Carmen B
Kacso, Gabriel
description Glioblastoma stem cells (GSCs), responsible for the dismal disease prognosis after conventional treatments, are driven by overactive signaling pathways, such as PI3K/ AKT/mTOR and RAS/RAF/MAPK. The objective of our study was to target in vitro-GSCs by combining metformin (Met) as a mTOR inhibitor, with sorafenib (Soraf) as a RAF inhibitor. GSCs cultured under basal conditions were treated with Met, temozolomide (TMZ), Soraf, Met+TMZ and Met+Soraf; as untreated arm served as control. At 4 hrs of drug exposure, we measured the level of reactive oxygen species (ROS) by 2',7'-dichlorofluorescein diacetate (DCFDA) assay, apoptosis by prodium iodide (PI)-V Annexin staining and efflux pump activity by using the fluorescent dye rhodamine 123. At 24 hrs, we measured cell proliferation by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay, apoptosis and malondialdehyde (MDA) levels. MTT results were compared with corresponding measurements on cultures of non-stem glioblastoma cells and osteoblasts. Met+Soraf exerted the highest antiproliferative effects in GSCs and non-stem glioblastoma cells (p
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1541369355</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1541369355</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-8ecd29c3c9e63126daa2b881bea39be42c02590917a9c033471e43b23dc63b4a3</originalsourceid><addsrcrecordid>eNo1kD1PwzAYhD2AaFX6F5BHlkj-SJx4RBVfUhELTAyR7bxpDXYc8jpD-fW0otxyy6PT3V2QJeesLpgS1YKsET_ZUYpxpZsrshClVlXJ5ZJ8vEDu0xT9QMcwI8U0mR4Gb-ne7_bhQH0cjctIM8T0k0KKvgM6AXrMZsh0F3yywWBO0VA8QkXwX0AdhIDX5LI3AWF99hV5f7h_2zwV29fH583dthgF57lowHVCO-k0KMmF6owRtmm4BSO1hVI4JirNNK-NdkzKsuZQSitk55S0pZErcvuXO07pewbMbfR4amAGSDO2_DRVaVlVR_TmjM42QteOk49mOrT_h8hf9C1dzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1541369355</pqid></control><display><type>article</type><title>Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Aldea, Mihaela D ; Petrushev, Bobe ; Soritau, Olga ; Tomuleasa, Ciprian I ; Berindan-Neagoe, Ioana ; Filip, Adriana G ; Chereches, Gabriela ; Cenariu, Mihai ; Craciun, Lucian ; Tatomir, Corina ; Florian, Ioan-Stefan ; Crivii, Carmen B ; Kacso, Gabriel</creator><creatorcontrib>Aldea, Mihaela D ; Petrushev, Bobe ; Soritau, Olga ; Tomuleasa, Ciprian I ; Berindan-Neagoe, Ioana ; Filip, Adriana G ; Chereches, Gabriela ; Cenariu, Mihai ; Craciun, Lucian ; Tatomir, Corina ; Florian, Ioan-Stefan ; Crivii, Carmen B ; Kacso, Gabriel</creatorcontrib><description>Glioblastoma stem cells (GSCs), responsible for the dismal disease prognosis after conventional treatments, are driven by overactive signaling pathways, such as PI3K/ AKT/mTOR and RAS/RAF/MAPK. The objective of our study was to target in vitro-GSCs by combining metformin (Met) as a mTOR inhibitor, with sorafenib (Soraf) as a RAF inhibitor. GSCs cultured under basal conditions were treated with Met, temozolomide (TMZ), Soraf, Met+TMZ and Met+Soraf; as untreated arm served as control. At 4 hrs of drug exposure, we measured the level of reactive oxygen species (ROS) by 2',7'-dichlorofluorescein diacetate (DCFDA) assay, apoptosis by prodium iodide (PI)-V Annexin staining and efflux pump activity by using the fluorescent dye rhodamine 123. At 24 hrs, we measured cell proliferation by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay, apoptosis and malondialdehyde (MDA) levels. MTT results were compared with corresponding measurements on cultures of non-stem glioblastoma cells and osteoblasts. Met+Soraf exerted the highest antiproliferative effects in GSCs and non-stem glioblastoma cells (p&lt;0.001). Both Met and Soraf monotherapy exhibited a selective cytotoxic effect on GSCs (p&lt;0.001), while no effect was detected on non-stem glioblastoma cells (p&gt;0.05). Soraf, but not Met, impacted the proliferation of normal cells. Soraf displayed synergism with Met in producing high levels of ROS, decreasing efflux pump activity and generating the highest apoptotic rates when compared to either drug alone (p&lt;0.001). GSCs were highly sensitive to the combination of Met and Soraf which reduced cell proliferation, increased oxidative stress, inhibited efflux pump activity and ultimately killed GSCs. We strongly believe that these results warrant further in vivo exploration.</description><identifier>ISSN: 1107-0625</identifier><identifier>PMID: 24965413</identifier><language>eng</language><publisher>Greece</publisher><subject><![CDATA[Apoptosis - drug effects ; Brain Neoplasms - drug therapy ; Brain Neoplasms - pathology ; Dacarbazine - analogs & derivatives ; Dacarbazine - therapeutic use ; Drug Resistance, Neoplasm ; Glioblastoma - drug therapy ; Glioblastoma - pathology ; Humans ; Lipid Peroxidation ; Metformin - administration & dosage ; Neoplastic Stem Cells - drug effects ; Neoplastic Stem Cells - metabolism ; Niacinamide - administration & dosage ; Niacinamide - analogs & derivatives ; Oxidative Stress ; Phenylurea Compounds - administration & dosage ; raf Kinases - antagonists & inhibitors ; Rhodamine 123 - metabolism ; TOR Serine-Threonine Kinases - antagonists & inhibitors]]></subject><ispartof>Journal of B.U. ON., 2014-04, Vol.19 (2), p.502-511</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24965413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aldea, Mihaela D</creatorcontrib><creatorcontrib>Petrushev, Bobe</creatorcontrib><creatorcontrib>Soritau, Olga</creatorcontrib><creatorcontrib>Tomuleasa, Ciprian I</creatorcontrib><creatorcontrib>Berindan-Neagoe, Ioana</creatorcontrib><creatorcontrib>Filip, Adriana G</creatorcontrib><creatorcontrib>Chereches, Gabriela</creatorcontrib><creatorcontrib>Cenariu, Mihai</creatorcontrib><creatorcontrib>Craciun, Lucian</creatorcontrib><creatorcontrib>Tatomir, Corina</creatorcontrib><creatorcontrib>Florian, Ioan-Stefan</creatorcontrib><creatorcontrib>Crivii, Carmen B</creatorcontrib><creatorcontrib>Kacso, Gabriel</creatorcontrib><title>Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells</title><title>Journal of B.U. ON.</title><addtitle>J BUON</addtitle><description>Glioblastoma stem cells (GSCs), responsible for the dismal disease prognosis after conventional treatments, are driven by overactive signaling pathways, such as PI3K/ AKT/mTOR and RAS/RAF/MAPK. The objective of our study was to target in vitro-GSCs by combining metformin (Met) as a mTOR inhibitor, with sorafenib (Soraf) as a RAF inhibitor. GSCs cultured under basal conditions were treated with Met, temozolomide (TMZ), Soraf, Met+TMZ and Met+Soraf; as untreated arm served as control. At 4 hrs of drug exposure, we measured the level of reactive oxygen species (ROS) by 2',7'-dichlorofluorescein diacetate (DCFDA) assay, apoptosis by prodium iodide (PI)-V Annexin staining and efflux pump activity by using the fluorescent dye rhodamine 123. At 24 hrs, we measured cell proliferation by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay, apoptosis and malondialdehyde (MDA) levels. MTT results were compared with corresponding measurements on cultures of non-stem glioblastoma cells and osteoblasts. Met+Soraf exerted the highest antiproliferative effects in GSCs and non-stem glioblastoma cells (p&lt;0.001). Both Met and Soraf monotherapy exhibited a selective cytotoxic effect on GSCs (p&lt;0.001), while no effect was detected on non-stem glioblastoma cells (p&gt;0.05). Soraf, but not Met, impacted the proliferation of normal cells. Soraf displayed synergism with Met in producing high levels of ROS, decreasing efflux pump activity and generating the highest apoptotic rates when compared to either drug alone (p&lt;0.001). GSCs were highly sensitive to the combination of Met and Soraf which reduced cell proliferation, increased oxidative stress, inhibited efflux pump activity and ultimately killed GSCs. We strongly believe that these results warrant further in vivo exploration.</description><subject>Apoptosis - drug effects</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - pathology</subject><subject>Dacarbazine - analogs &amp; derivatives</subject><subject>Dacarbazine - therapeutic use</subject><subject>Drug Resistance, Neoplasm</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - pathology</subject><subject>Humans</subject><subject>Lipid Peroxidation</subject><subject>Metformin - administration &amp; dosage</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Neoplastic Stem Cells - metabolism</subject><subject>Niacinamide - administration &amp; dosage</subject><subject>Niacinamide - analogs &amp; derivatives</subject><subject>Oxidative Stress</subject><subject>Phenylurea Compounds - administration &amp; dosage</subject><subject>raf Kinases - antagonists &amp; inhibitors</subject><subject>Rhodamine 123 - metabolism</subject><subject>TOR Serine-Threonine Kinases - antagonists &amp; inhibitors</subject><issn>1107-0625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kD1PwzAYhD2AaFX6F5BHlkj-SJx4RBVfUhELTAyR7bxpDXYc8jpD-fW0otxyy6PT3V2QJeesLpgS1YKsET_ZUYpxpZsrshClVlXJ5ZJ8vEDu0xT9QMcwI8U0mR4Gb-ne7_bhQH0cjctIM8T0k0KKvgM6AXrMZsh0F3yywWBO0VA8QkXwX0AdhIDX5LI3AWF99hV5f7h_2zwV29fH583dthgF57lowHVCO-k0KMmF6owRtmm4BSO1hVI4JirNNK-NdkzKsuZQSitk55S0pZErcvuXO07pewbMbfR4amAGSDO2_DRVaVlVR_TmjM42QteOk49mOrT_h8hf9C1dzw</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Aldea, Mihaela D</creator><creator>Petrushev, Bobe</creator><creator>Soritau, Olga</creator><creator>Tomuleasa, Ciprian I</creator><creator>Berindan-Neagoe, Ioana</creator><creator>Filip, Adriana G</creator><creator>Chereches, Gabriela</creator><creator>Cenariu, Mihai</creator><creator>Craciun, Lucian</creator><creator>Tatomir, Corina</creator><creator>Florian, Ioan-Stefan</creator><creator>Crivii, Carmen B</creator><creator>Kacso, Gabriel</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140401</creationdate><title>Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells</title><author>Aldea, Mihaela D ; Petrushev, Bobe ; Soritau, Olga ; Tomuleasa, Ciprian I ; Berindan-Neagoe, Ioana ; Filip, Adriana G ; Chereches, Gabriela ; Cenariu, Mihai ; Craciun, Lucian ; Tatomir, Corina ; Florian, Ioan-Stefan ; Crivii, Carmen B ; Kacso, Gabriel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-8ecd29c3c9e63126daa2b881bea39be42c02590917a9c033471e43b23dc63b4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Apoptosis - drug effects</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - pathology</topic><topic>Dacarbazine - analogs &amp; derivatives</topic><topic>Dacarbazine - therapeutic use</topic><topic>Drug Resistance, Neoplasm</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - pathology</topic><topic>Humans</topic><topic>Lipid Peroxidation</topic><topic>Metformin - administration &amp; dosage</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Neoplastic Stem Cells - metabolism</topic><topic>Niacinamide - administration &amp; dosage</topic><topic>Niacinamide - analogs &amp; derivatives</topic><topic>Oxidative Stress</topic><topic>Phenylurea Compounds - administration &amp; dosage</topic><topic>raf Kinases - antagonists &amp; inhibitors</topic><topic>Rhodamine 123 - metabolism</topic><topic>TOR Serine-Threonine Kinases - antagonists &amp; inhibitors</topic><toplevel>online_resources</toplevel><creatorcontrib>Aldea, Mihaela D</creatorcontrib><creatorcontrib>Petrushev, Bobe</creatorcontrib><creatorcontrib>Soritau, Olga</creatorcontrib><creatorcontrib>Tomuleasa, Ciprian I</creatorcontrib><creatorcontrib>Berindan-Neagoe, Ioana</creatorcontrib><creatorcontrib>Filip, Adriana G</creatorcontrib><creatorcontrib>Chereches, Gabriela</creatorcontrib><creatorcontrib>Cenariu, Mihai</creatorcontrib><creatorcontrib>Craciun, Lucian</creatorcontrib><creatorcontrib>Tatomir, Corina</creatorcontrib><creatorcontrib>Florian, Ioan-Stefan</creatorcontrib><creatorcontrib>Crivii, Carmen B</creatorcontrib><creatorcontrib>Kacso, Gabriel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of B.U. ON.</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aldea, Mihaela D</au><au>Petrushev, Bobe</au><au>Soritau, Olga</au><au>Tomuleasa, Ciprian I</au><au>Berindan-Neagoe, Ioana</au><au>Filip, Adriana G</au><au>Chereches, Gabriela</au><au>Cenariu, Mihai</au><au>Craciun, Lucian</au><au>Tatomir, Corina</au><au>Florian, Ioan-Stefan</au><au>Crivii, Carmen B</au><au>Kacso, Gabriel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells</atitle><jtitle>Journal of B.U. ON.</jtitle><addtitle>J BUON</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>19</volume><issue>2</issue><spage>502</spage><epage>511</epage><pages>502-511</pages><issn>1107-0625</issn><abstract>Glioblastoma stem cells (GSCs), responsible for the dismal disease prognosis after conventional treatments, are driven by overactive signaling pathways, such as PI3K/ AKT/mTOR and RAS/RAF/MAPK. The objective of our study was to target in vitro-GSCs by combining metformin (Met) as a mTOR inhibitor, with sorafenib (Soraf) as a RAF inhibitor. GSCs cultured under basal conditions were treated with Met, temozolomide (TMZ), Soraf, Met+TMZ and Met+Soraf; as untreated arm served as control. At 4 hrs of drug exposure, we measured the level of reactive oxygen species (ROS) by 2',7'-dichlorofluorescein diacetate (DCFDA) assay, apoptosis by prodium iodide (PI)-V Annexin staining and efflux pump activity by using the fluorescent dye rhodamine 123. At 24 hrs, we measured cell proliferation by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay, apoptosis and malondialdehyde (MDA) levels. MTT results were compared with corresponding measurements on cultures of non-stem glioblastoma cells and osteoblasts. Met+Soraf exerted the highest antiproliferative effects in GSCs and non-stem glioblastoma cells (p&lt;0.001). Both Met and Soraf monotherapy exhibited a selective cytotoxic effect on GSCs (p&lt;0.001), while no effect was detected on non-stem glioblastoma cells (p&gt;0.05). Soraf, but not Met, impacted the proliferation of normal cells. Soraf displayed synergism with Met in producing high levels of ROS, decreasing efflux pump activity and generating the highest apoptotic rates when compared to either drug alone (p&lt;0.001). GSCs were highly sensitive to the combination of Met and Soraf which reduced cell proliferation, increased oxidative stress, inhibited efflux pump activity and ultimately killed GSCs. We strongly believe that these results warrant further in vivo exploration.</abstract><cop>Greece</cop><pmid>24965413</pmid><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1107-0625
ispartof Journal of B.U. ON., 2014-04, Vol.19 (2), p.502-511
issn 1107-0625
language eng
recordid cdi_proquest_miscellaneous_1541369355
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Apoptosis - drug effects
Brain Neoplasms - drug therapy
Brain Neoplasms - pathology
Dacarbazine - analogs & derivatives
Dacarbazine - therapeutic use
Drug Resistance, Neoplasm
Glioblastoma - drug therapy
Glioblastoma - pathology
Humans
Lipid Peroxidation
Metformin - administration & dosage
Neoplastic Stem Cells - drug effects
Neoplastic Stem Cells - metabolism
Niacinamide - administration & dosage
Niacinamide - analogs & derivatives
Oxidative Stress
Phenylurea Compounds - administration & dosage
raf Kinases - antagonists & inhibitors
Rhodamine 123 - metabolism
TOR Serine-Threonine Kinases - antagonists & inhibitors
title Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T17%3A28%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metformin%20plus%20sorafenib%20highly%20impacts%20temozolomide%20resistant%20glioblastoma%20stem-like%20cells&rft.jtitle=Journal%20of%20B.U.%20ON.&rft.au=Aldea,%20Mihaela%20D&rft.date=2014-04-01&rft.volume=19&rft.issue=2&rft.spage=502&rft.epage=511&rft.pages=502-511&rft.issn=1107-0625&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1541369355%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1541369355&rft_id=info:pmid/24965413&rfr_iscdi=true